Clinical Trial: A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07582133) titled 'A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy' on May 06.

Brief Summary: This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Primary IgA Nephropathy

Intervention: DRUG: HRS-5965 Capsules

HRS-5965 Capsules

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chengdu Suncadia Medicine Co., Ltd.

Disclaimer: Curated by HT Syndi...